MetLife Investment Management Buys $22M of CCD Series I Preferred Shares After Series D Redemption
CCD sits 25% above its 52-week low of $19.985 on light trading volume (0.4× avg).
Summary
MetLife Investment Management bought $22 million of CCD Series I preferred shares at $25.00 per share, two days after the fund redeemed its Series D preferred shares.
Key Events · Ownership and Investor Activity · CCD
-
MetLife Buys $22M Series I Preferred
MetLife Investment Management, LLC acquired 880,000 Series I Mandatory Redeemable Preferred Shares at $25.00 per share for $22,000,000 on August 26, 2026.
-
Series D Redemption Completed
The fund redeemed 440,000 Series D Mandatory Redeemable Preferred Shares at $25.00 per share on August 24, 2026, as previously announced on July 23, 2026.
-
Major Holder Reinvests
The purchase by a 10% owner represents a significant reinvestment in the fund's preferred share structure following the removal of $28 million of senior capital.
Analysis · CCD · Unknown
MetLife Investment Management, LLC, a 10% owner of Calamos Dynamic Convertible & Income Fund, purchased 880,000 Series I Mandatory Redeemable Preferred Shares for $22 million at $25.00 per share on August 26, 2026. This follows the full redemption of the fund's Series D preferred shares on August 24, 2026, which removed $28 million of senior capital. The purchase represents a significant reinvestment by a major institutional holder, signaling continued confidence in the fund's preferred share structure.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CCD was trading at $25.04 on NASDAQ in the Unknown sector, with a market capitalization of approximately $700M. The 52-week trading range was $19.99 to $26.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.